RT Journal Article
SR Electronic
A1 Gordon, Debra
T1 ACT Trial Results Should Change Clinical Practice
JF MD Conference Express
YR 2010
FD SAGE Publications
VO 10
IS 10
SP 16
OP 17
DO 10.1177/155989771010008
UL http://mdc.sagepub.com/content/10/10/16.abstract
AB Based on the results of the Acetylcysteine for the prevention of Contrast-Induced nephropathy [ACT; NCT00736866] trial, there is no evidence that the antioxidant N-acetylcysteine reduces the risk of contrast-induced nephropathy in patients who are undergoing coronary and vascular angiography.